SpyGlass Pharma, a biopharmaceutical clinical-stage company dedicated to transforming treatment for patients living with chronic eye conditions, today celebrated the grand opening of its new Irvine headquarters, marking a pivotal point in the company's growth.
The opening of its 33,000-square-foot headquarters August 27 is a homecoming for SpyGlass Pharma, which established its first laboratory space in Irvine in 2021 before expanding to a larger facility in Aliso Viejo. After advancing its lead product candidate from the R&D phase to launch two robust Phase 3 clinical trials, the company outgrew its former facility following a successful IPO in February 2026, along with a strengthened leadership team and increased headcount. SpyGlass Pharma looked to expand its footprint as it plans to scale up for commercialization of its innovative sustained drug delivery system and advance its ophthalmology pipeline.
"This is a special moment for SpyGlass," said Patrick Mooney, CEO of SpyGlass Pharma. "Our roots have always been in Orange County, and now we're thrilled to move our headquarters to Irvine for this significant growth phase of the company. Irvine has been a hub for innovation, and it only makes sense that SpyGlass is centrally located as we gear up for our first product launch and continue to develop additional innovative sustained drug delivery products for patients with chronic eye conditions."
Since completing its initial public offering in February 2026, which raised $172.5 million in gross proceeds, SpyGlass Pharma has grown its workforce by 33% and now employs more than 85 people.
"SpyGlass Pharma's decision to move to Irvine underscores our City's standing as a premier destination for growing businesses," said Mayor Larry Agran. "We are proud to welcome them back to our vibrant economic community."
The new headquarters also provides expanded product development space as SpyGlass prepares for its next phase of growth.
"Significantly expanding our operation in Irvine gives SpyGlass access to world-class talent in the competitive biotech environment," said James Dennewill, COO of SpyGlass Pharma. "The local talent, fed by a top-ranked public research university, combined with the expanded innovation space, will fuel SpyGlass innovation for years to come. For a company focused on enduring vision, we're excited to be partnering with a City that has built an enduring ecosystem for innovative medical technologies for over 50 years."
